ENSYSCE BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of -$296 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2025-03-10
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was -$296.00.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was -$3.85K, a 107.09% decline from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2022 was $54.26K, a 85.40% decline from fiscal 2021.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2021 was $371.78K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2024-12-31 | -$296.00 10-K · filed 2025-03-10 |
| 2023-12-31 | -$3.85K 10-K · filed 2025-03-10 |
| 2022-12-31 | $54.26K 10-K · filed 2024-03-15 |
| 2021-12-31 | $371.78K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |